Macrophages as a “weapon” in anticancer cellular immunotherapy

Dmitry Aminin*, Yun-Ming Wang

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

40 Scopus citations

Abstract

Anticancer immunotherapy is a treatment that activates the immune system to fight the tumor. Immunotherapy has several advantages over other cancer treatments in that anticancer immunotherapy displays high specificity, low side effects, and can combine with various conventional therapies. In recent years, oncologists have shown increasing interest in using macrophages for adoptive cell therapy and predict a bright future of macrophage-directed therapy for eliminating cancer. The focus of increased research interest is the classically activated M1 macrophages exhibiting pronounced tumoricidal activity, and the alternatively activated M2 tumor-associated macrophages, which otherwise help malignant cells evading attack by the immune system. M1 macrophages may represent an effective weapon in anticancer cellular immunotherapy, and the use of autoimmune macrophages properly prepared for antitumor administration is one of the promising ways for personalized therapy of cancer patients. The present report mainly discusses some modern aspects of the problem in application of activated M1 macrophage in anticancer therapy and reviews relevant publications up to 2021.

Original languageEnglish
Pages (from-to)749-758
Number of pages10
JournalKaohsiung Journal of Medical Sciences
Volume37
Issue number9
DOIs
StatePublished - Sep 2021

Keywords

  • M1 phenotype
  • anticancer cellular immunotherapy
  • cancer
  • macrophages

Fingerprint

Dive into the research topics of 'Macrophages as a “weapon” in anticancer cellular immunotherapy'. Together they form a unique fingerprint.

Cite this